DMTA

DeepMirror Launches Early Access Programme for Its Intuitive Molecular Drug Design Software

Retrieved on: 
Monday, December 11, 2023

DeepMirror, a University of Cambridge spin-out company developing intuitive design software for the discovery of novel therapeutic drugs, today announced the launch of its Early Access Programme after a successful closed beta programme during which chemists were invited to test the software over several months.

Key Points: 
  • DeepMirror, a University of Cambridge spin-out company developing intuitive design software for the discovery of novel therapeutic drugs, today announced the launch of its Early Access Programme after a successful closed beta programme during which chemists were invited to test the software over several months.
  • The software allows users to tap into AI-driven insights to improve and accelerate molecular design across the drug discovery pipeline through a secure and user-friendly interface which makes AI-powered drug discovery as simple as using a spreadsheet.
  • AI-enabled drug discovery programmes often start with pharmaceutical companies partnering with AI companies to deliver insights for their drug discovery efforts.
  • After 12 months of development and a successful beta testing programme, we are excited to officially launch DeepMirror to early adopters.

Enamine and BioSolveIT Embark on Exclusive Partnership

Retrieved on: 
Wednesday, December 13, 2023

Chief research chemicals provider Enamine and software innovator BioSolveIT have officially joined forces to establish the world's most comprehensive chemical space exploration platform.

Key Points: 
  • Chief research chemicals provider Enamine and software innovator BioSolveIT have officially joined forces to establish the world's most comprehensive chemical space exploration platform.
  • View the full release here: https://www.businesswire.com/news/home/20231211141956/en/
    The alliance between BioSolveIT and Enamine will be game-changing in the pursuit of innovation within the pharma industry.
  • Professor Dr. Andrey Tolmachov, Founder and CEO at Enamine, says: "Over the past few years, BioSolveIT has taken virtual screening to a whole new level.
  • Whomever you ask, Enamine is their first choice when it comes to compound sourcing with the highest reliability at unprecedented speed.

Accelerating Drug Discovery by Hypothesis and Synthesis Management Platform, Upcoming Webinar Hosted by Xtalks

Retrieved on: 
Wednesday, October 25, 2023

TORONTO, Oct. 25, 2023 /PRNewswire-PRWeb/ -- Discover an innovative webinar exploring the importance of using a hypothesis and synthesis management platform to accelerate drug discovery. Design, make, test and analyze (DMTA) project teams encounter several challenges when it comes to deciding which compounds to synthesize next. These challenges include:

Key Points: 
  • In this free webinar, discover how to overcome various challenges of compound synthesis and decision-making in drug discovery.
  • TORONTO, Oct. 25, 2023 /PRNewswire-PRWeb/ -- Discover an innovative webinar exploring the importance of using a hypothesis and synthesis management platform to accelerate drug discovery.
  • Join this webinar and discover how to overcome various challenges of compound synthesis and decision-making in drug discovery.
  • Join Dóra Barna, PhD, Principal Application Scientist, Chemaxon , for the live webinar on Friday, November 10, 2023, at 11am EST (4pm GMT/UK).

Fujitsu launches "Biodrug Design Accelerator" platform to accelerate peptide drug discovery research

Retrieved on: 
Thursday, May 18, 2023

Biodrug Design Accelerator will support peptide drug discovery scientists in pharmaceutical companies to accelerate and improve the efficiency of peptide drug development, specifically through the cycles "design, make, test, analyze" (DMTA) (2), ultimately enabling accelerated and informed design of peptide drug candidates as well as efficient communication among scientists regarding synthesis and testing.

Key Points: 
  • Biodrug Design Accelerator will support peptide drug discovery scientists in pharmaceutical companies to accelerate and improve the efficiency of peptide drug development, specifically through the cycles "design, make, test, analyze" (DMTA) (2), ultimately enabling accelerated and informed design of peptide drug candidates as well as efficient communication among scientists regarding synthesis and testing.
  • PeptiDream offered support in the research and development of the new drug discovery platform as well as in the evaluation of its different functions and operability.
  • We hope that many pharmaceutical companies will successfully introduce this platform to their business to realize the full potential of peptide drug discovery.
  • To address these inefficiencies and ultimately accelerate the peptide drug design lifecycle, Fujitsu launched Biodrug Design Accelerator, a web-based compound design and collaboration platform that enables diverse scientists at different stages of the drug design lifecycle to consolidate data in a single integrated solution.

Helios Technologies’ Strategy Drives Another Record Year of Product Line and Technological Innovation within its Hydraulics Segment

Retrieved on: 
Monday, February 27, 2023

Over the years, Helios has built a powerful portfolio of assets and technologies in the hydraulics industry both organically, and through acquisition.

Key Points: 
  • Over the years, Helios has built a powerful portfolio of assets and technologies in the hydraulics industry both organically, and through acquisition.
  • Josef Matosevic, Helios’ President, and Chief Executive Officer, commented, “Helios Technologies has a long history of innovation leadership.
  • This collection of market leading hydraulic product releases and integrated solutions further demonstrate the power of our strategy as we leverage our research and development across our businesses.
  • Over the years, Helios has enhanced its Hydraulics capabilities, end markets, and geographies through organic investments and a disciplined and targeted acquisition strategy.

Genedata Screener 20 Further Accelerates and Digitalizes Assay Data Workflows -- To Be Showcased at SLAS2023

Retrieved on: 
Tuesday, February 21, 2023

BASEL, Switzerland, Feb. 21, 2023 /PRNewswire-PRWeb/ -- Genedata, the leading provider of enterprise software solutions for biopharmaceutical R&D, today announced the release of Genedata Screener® 20. The most comprehensive digital platform for assay analysis in Biopharma R&D, Genedata Screener shortens design-make-test-analyze (DMTA) cycles in R&D through real-time data capture and automated analysis of simple and complex assays. It consolidates and FAIRifies assay information across the enterprise, including with CROs and other external collaborators. Genedata Screener provides easy access to fully integrated, up-to-date assay information to global R&D teams, providing significant time savings, and enabling efficient decision-making.

Key Points: 
  • The new Genedata Screener 20 will be featured among SLAS2023 Tutorial Sessions and demonstrated at SLAS Booth #1044 (February 25 – March 1; San Diego Convention Center).
  • Genedata Screener tremendously increases the ROI of those investments by automating the corresponding data workflows," noted Othmar Pfannes, Ph.D., CEO of Genedata.
  • "Genedata Screener intelligently captures and integrates experimental data directly from a variety of analytical instruments, ensuring that only data of the highest quality enters the automated data analysis workflows.
  • Genedata Screener digitalizes assay workflows and integrates and condenses complex experimental data to power efficient project decisions.

XtalPi Announces Research Collaboration with Janssen

Retrieved on: 
Thursday, October 27, 2022

SHENZHEN, China, Oct. 27, 2022 /PRNewswire/ -- XtalPi, Inc., a privately-held solution provider accelerating biopharmaceutical research via its integrated technology platform, announced a research collaboration with Janssen Pharmaceutica NV, one of the Janssen Pharmaceutical Companies of Johnson & Johnson ("Janssen") to deliver chemical matter with validated binding affinities and desirable property profiles.

Key Points: 
  • SHENZHEN, China, Oct. 27, 2022 /PRNewswire/ -- XtalPi, Inc., a privately-held solution provider accelerating biopharmaceutical research via its integrated technology platform, announced a research collaboration with Janssen Pharmaceutica NV, one of the Janssen Pharmaceutical Companies of Johnson & Johnson ("Janssen") to deliver chemical matter with validated binding affinities and desirable property profiles.
  • Under the agreement, XtalPi will deliver validated small molecule hits that possess defined properties for a given target nominated by Janssen.
  • Since then, XtalPi has maintained its focus on identifying and then attacking traditional bottlenecks in biopharmaceutical R&D through innovative technologies.
  • XtalPi has engaged in collaboration research with nearly all top-20 pharmaceutical companies in the world.

Chemaxon Joins the Tetra Partner Network to Help Customers Accelerate Drug Delivery

Retrieved on: 
Wednesday, June 29, 2022

"Chemaxon is an industry leader with flexible solutions that support computational chemistry,"said Simon Meffan-Main, Ph.D., Vice President, Tetra Partner Network.

Key Points: 
  • "Chemaxon is an industry leader with flexible solutions that support computational chemistry,"said Simon Meffan-Main, Ph.D., Vice President, Tetra Partner Network.
  • Trusted by over one million active users, Chemaxon is renownedfor industry-leadingsoftware supporting scientific discovery with calculation, search and drawing tools.
  • "By partnering with TetraScience, Chemaxon can automatically ingest Tetra Data so that customers can analyze more scientific data at faster speeds and with greater ease," said Richard Jones, CEO, Chemaxon.
  • We are thrilled to partner with TetraScience and use Tetra Data to help customers accelerate chemical compound discovery, development and manufacturing."

Strateos Launches Rapid Idea-to-Data Solution for Small Molecule Discovery on its Cloud Lab Automation-as-a-Service Platform

Retrieved on: 
Thursday, April 7, 2022

Strateos continues to introduce flexible solutions for drug discovery teams seeking state-of-the-art ways to advance small molecule programs, said John Harman, Sr. Director of Product Management at Strateos.

Key Points: 
  • Strateos continues to introduce flexible solutions for drug discovery teams seeking state-of-the-art ways to advance small molecule programs, said John Harman, Sr. Director of Product Management at Strateos.
  • The on-demand, scalable Strateos Cloud Lab Automation-as-a-Service Platform features connected robotic automation utilizing 23 workcells and hundreds of instruments.
  • Strateos is a pioneer in the development of remote access laboratories and lab automation software for life science discovery.
  • The Strateos Cloud Lab Automation-as-a-Service Platform helps scientists more efficiently and reproducibly design, run, and analyze experiments to achieve new and faster scientific discoveries.

Aerobotix-Powered Mobile Robot Helps Compass Technology Group Win Top Defense Manufacturing Technology Award

Retrieved on: 
Tuesday, February 15, 2022

Aerobotix , an AS9100 certified FANUC robotics integrator and metrology company, today officially congratulated key partner Compass Technology Group (CTG) on winning the top Defense Manufacturing Technology Achievement Award (DMTAA) at the recent Defense Manufacturing Conference (DMC).

Key Points: 
  • Aerobotix , an AS9100 certified FANUC robotics integrator and metrology company, today officially congratulated key partner Compass Technology Group (CTG) on winning the top Defense Manufacturing Technology Achievement Award (DMTAA) at the recent Defense Manufacturing Conference (DMC).
  • View the full release here: https://www.businesswire.com/news/home/20220215005483/en/
    Aerobotixs automated guided vehicle (or mobile robot), along with the Advanced Microwave Mapping Probe, developed by Compass Technology Group.
  • (Photo: Business Wire)
    Aerobotix is extremely proud and honored to have assisted Compass Technology Group in this endeavor, said Josh Tuttle, Business Development Manager at Aerobotix.
  • From a quality control standpoint, this technology could be used to save substantial amounts of money for organizations and further increase means of production and manufacturing.